Diagnosis & Disease Information

Leah Lawrence

June 10, 2022

The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.

Jonathan Goodman, MPhil

June 10, 2022

Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.

June 10, 2022

Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.

June 10, 2022

A large proportion of patients with relapsed/refractory diffuse large B-cell lymphoma do not undergo repeat biopsy, a study suggests.

Next post in EHA 2022

Zandelisib Displays “Exemplary” Efficacy in Relapsed/Refractory Follicular Lymphoma